A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in diabetes prevention trial-type 1 (DPT-1) participants

Jay M Sosenko, Jay S Skyler, Jerry P. Palmer, Jeffrey P. Krischer, David Cuthbertson, Liping Yu, Desmond A. Schatz, Tihamer Orban, George Eisenbarth

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

OBJECTIVE - We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS - Diabetes Prevention Trial-Type 1 (DPT-1) participants were assessed for changes in positivity and titers of GADA and IA-2A during the progression to T1D. RESULTS - Among 99 progressors to T1D with GADA and IA-2A measurements at baseline and diagnosis (mean interval = 3.3 ± 1.5 years), GADA positivity changed little and GADA titers decreased (P < 0.01). In contrast, both IA-2A positivity and titers increased substantially (P < 0.001). Even among those positive at baseline, IA-2A titers increased from baseline to diagnosis (n = 57; P < 0.001), whereas GADA titers decreased (n = 80; P < 0.01). The same patterns of change were also evident among those positive for both autoantibodies (n = 48) at baseline. CONCLUSIONS - IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A. In contrast, GADA titers tend to decline during those years.

Original languageEnglish
Pages (from-to)2435-2437
Number of pages3
JournalDiabetes Care
Volume34
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Type 1 Diabetes Mellitus
Longitudinal Studies
Autoantibodies
Research Design
ICA512 autoantibody

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in diabetes prevention trial-type 1 (DPT-1) participants. / Sosenko, Jay M; Skyler, Jay S; Palmer, Jerry P.; Krischer, Jeffrey P.; Cuthbertson, David; Yu, Liping; Schatz, Desmond A.; Orban, Tihamer; Eisenbarth, George.

In: Diabetes Care, Vol. 34, No. 11, 01.11.2011, p. 2435-2437.

Research output: Contribution to journalArticle

Sosenko, Jay M ; Skyler, Jay S ; Palmer, Jerry P. ; Krischer, Jeffrey P. ; Cuthbertson, David ; Yu, Liping ; Schatz, Desmond A. ; Orban, Tihamer ; Eisenbarth, George. / A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in diabetes prevention trial-type 1 (DPT-1) participants. In: Diabetes Care. 2011 ; Vol. 34, No. 11. pp. 2435-2437.
@article{61345b4053544592aaad655dd4367356,
title = "A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in diabetes prevention trial-type 1 (DPT-1) participants",
abstract = "OBJECTIVE - We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS - Diabetes Prevention Trial-Type 1 (DPT-1) participants were assessed for changes in positivity and titers of GADA and IA-2A during the progression to T1D. RESULTS - Among 99 progressors to T1D with GADA and IA-2A measurements at baseline and diagnosis (mean interval = 3.3 ± 1.5 years), GADA positivity changed little and GADA titers decreased (P < 0.01). In contrast, both IA-2A positivity and titers increased substantially (P < 0.001). Even among those positive at baseline, IA-2A titers increased from baseline to diagnosis (n = 57; P < 0.001), whereas GADA titers decreased (n = 80; P < 0.01). The same patterns of change were also evident among those positive for both autoantibodies (n = 48) at baseline. CONCLUSIONS - IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A. In contrast, GADA titers tend to decline during those years.",
author = "Sosenko, {Jay M} and Skyler, {Jay S} and Palmer, {Jerry P.} and Krischer, {Jeffrey P.} and David Cuthbertson and Liping Yu and Schatz, {Desmond A.} and Tihamer Orban and George Eisenbarth",
year = "2011",
month = "11",
day = "1",
doi = "10.2337/dc11-0981",
language = "English",
volume = "34",
pages = "2435--2437",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in diabetes prevention trial-type 1 (DPT-1) participants

AU - Sosenko, Jay M

AU - Skyler, Jay S

AU - Palmer, Jerry P.

AU - Krischer, Jeffrey P.

AU - Cuthbertson, David

AU - Yu, Liping

AU - Schatz, Desmond A.

AU - Orban, Tihamer

AU - Eisenbarth, George

PY - 2011/11/1

Y1 - 2011/11/1

N2 - OBJECTIVE - We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS - Diabetes Prevention Trial-Type 1 (DPT-1) participants were assessed for changes in positivity and titers of GADA and IA-2A during the progression to T1D. RESULTS - Among 99 progressors to T1D with GADA and IA-2A measurements at baseline and diagnosis (mean interval = 3.3 ± 1.5 years), GADA positivity changed little and GADA titers decreased (P < 0.01). In contrast, both IA-2A positivity and titers increased substantially (P < 0.001). Even among those positive at baseline, IA-2A titers increased from baseline to diagnosis (n = 57; P < 0.001), whereas GADA titers decreased (n = 80; P < 0.01). The same patterns of change were also evident among those positive for both autoantibodies (n = 48) at baseline. CONCLUSIONS - IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A. In contrast, GADA titers tend to decline during those years.

AB - OBJECTIVE - We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS - Diabetes Prevention Trial-Type 1 (DPT-1) participants were assessed for changes in positivity and titers of GADA and IA-2A during the progression to T1D. RESULTS - Among 99 progressors to T1D with GADA and IA-2A measurements at baseline and diagnosis (mean interval = 3.3 ± 1.5 years), GADA positivity changed little and GADA titers decreased (P < 0.01). In contrast, both IA-2A positivity and titers increased substantially (P < 0.001). Even among those positive at baseline, IA-2A titers increased from baseline to diagnosis (n = 57; P < 0.001), whereas GADA titers decreased (n = 80; P < 0.01). The same patterns of change were also evident among those positive for both autoantibodies (n = 48) at baseline. CONCLUSIONS - IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A. In contrast, GADA titers tend to decline during those years.

UR - http://www.scopus.com/inward/record.url?scp=84857073928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857073928&partnerID=8YFLogxK

U2 - 10.2337/dc11-0981

DO - 10.2337/dc11-0981

M3 - Article

VL - 34

SP - 2435

EP - 2437

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -